Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

• Main Authors: Juanjuan Jiang (Author), Li Xu (Author), Lin Chai (Author), Xiaoyuan Guan (Author), Li Zhang (Author), Hong Liu (Author), Yan Yan (Author), Lili Li (Author), Yi Zhao (Author), Xuelian Bai (Author), Lei Tian (Author), Youhong Jia (Author)
• Format: Book
• Published: Wiley, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low‐density lipoprotein‐cholesterol (LDL‐C) by decreasing the expression of the LDL‐receptor on hepatic cells. Ongericimab (JS002) is a novel PCSK9 monoclonal antibody that exhibits a long‐acting LDL‐C lowering effect by...